Ilona A. Baraniak
London, ENG NW32PP, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
A temperature-dependent virus-binding assay reveals the presence of neutralizing antibodies in human cytomegalovirus gB vaccine recipients' sera.
Journal: The Journal of general virology
Published: June 13, 2023
The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread.
Journal: Nature communications
Published: June 11, 2021
Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease.
Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease.
Journal: The Journal of infectious diseases
Published: March 06, 2020
Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.
Journal: EBioMedicine
Published: July 16, 2019
Original Antigenic Sin Shapes the Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B/MF59 Vaccine in Seropositive Recipients.
Journal: The Journal of infectious diseases
Published: January 16, 2019
Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: April 25, 2018
Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia.
Journal: The Journal of infectious diseases
Published: October 16, 2017
Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient.
Journal: Reviews in medical virology
Published: July 17, 2017
The pathogenesis of human cytomegalovirus.
Journal: The Journal of pathology
Published: August 13, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026